OncoMatch/Clinical Trials/NCT06315491
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
Is NCT06315491 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies CBX-12 for platinum-resistant ovarian cancer.
Treatment: CBX-12 — The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy
Subjects who have received only 1 platinum-based chemotherapy regimen for at least 4 cycles of platinum must have disease progression on treatment or occurring ≤ 26 weeks after their last dose of platinum. Patients who have progressed following a second course of a platinum based regimen.
Cannot have received: cytotoxic chemotherapy
Exception: within 3 weeks prior to the first dose of CBX-12
Cytotoxic chemotherapy, biologic agent, investigational agent, or radiation therapy within 3 weeks prior to the first dose of CBX-12.
Cannot have received: biologic agent
Exception: within 3 weeks prior to the first dose of CBX-12
Cytotoxic chemotherapy, biologic agent, investigational agent, or radiation therapy within 3 weeks prior to the first dose of CBX-12.
Cannot have received: investigational agent
Exception: within 3 weeks prior to the first dose of CBX-12
Cytotoxic chemotherapy, biologic agent, investigational agent, or radiation therapy within 3 weeks prior to the first dose of CBX-12.
Cannot have received: radiation therapy
Exception: within 3 weeks prior to the first dose of CBX-12
Cytotoxic chemotherapy, biologic agent, investigational agent, or radiation therapy within 3 weeks prior to the first dose of CBX-12.
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Honor Health · Scottsdale, Arizona
- Arizona Oncology Associates · Tucson, Arizona
- Usc Norris Comprehensive Cancer Center · Los Angeles, California
- Yale University School of Medicine · New Haven, Connecticut
- D&H Cancer Research Center · Margate, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06315491 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cytotoxic chemotherapy, biologic agent, investigational agent disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages